We have a curated list of the most noteworthy news from all across the globe. With any subscription plan, you get access to exclusive articles that let you stay ahead of the curve.
We have a curated list of the most noteworthy news from all across the globe. With any subscription plan, you get access to exclusive articles that let you stay ahead of the curve.
We have a curated list of the most noteworthy news from all across the globe. With any subscription plan, you get access to exclusive articles that let you stay ahead of the curve.
/ forever
Sign up with just an email address and you get access to this tier instantly.
/ year
Pay now and you get access to exclusive news and articles for a whole year.
/ month
By agreeing to this tier, you are billed every month after the first one until you opt out of the monthly subscription.
/ forever
Sign up with just an email address and you get access to this tier instantly.
/ year
Pay now and you get access to exclusive news and articles for a whole year.
/ month
By agreeing to this tier, you are billed every month after the first one until you opt out of the monthly subscription.
We have a curated list of the most noteworthy news from all across the globe. With any subscription plan, you get access to exclusive articles that let you stay ahead of the curve.
HYDERABAD: Pharma major Dr Reddy’s Laboratories on Tuesday reported a 15% drop in consolidated net profit for the Sept quarter, despite its quarterly revenues surpassing the Rs 8,000-crore mark for the first time, primarily due to price erosion in the US generic market. Consolidated net profit for Q2 fell to Rs 1,255 crore from Rs 1,480 crore a year ago.
#DRL #net #falls #revenue #surge #Times #India
We have a curated list of the most noteworthy news from all across the globe. With any subscription plan, you get access to exclusive articles that let you stay ahead of the curve.
